First-in-Class Brain Cancer Drug Strikes a Chord With Jazz Pharma to the Tune of a $935M M&A Deal https://t.co/AcQw1cSBG8

Truist $JAZZ Dordaviprone Could Be Accretive Near Term. Promising Pipeline An Upside. Raising PT To $230 - This AM, JAZZ announced decision to acquire Chimerix $CMRX, NR) in an all cash transaction for $935M or $8.55 per share

#ZYDUSLIFE Zydus Lifescience jumps 3.15% on receiving USFDA final approval to manufacture Dasatinib Tablets (20 mg - 140 mg), a key drug for Ph+ CML & Ph+ ALL treatment. 💊 🔹 Manufactured at Zydus SEZ, Ahmedabad 🔹 US market size: $1.8B (IQVIA, Jan 2025) #StockMarket #Pharma…